Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
Celsion CorporationCondensed Statements of Operations(Unaudited)(in thousands except for per share amounts)Three Months
Ended September 30,Nine Months
Ended September 30,2010 20092010 2009 Operating expenses: Research and development
10,676General and administrative 1,2201,2243,5442514 Total operating expenses 5,1714,72714,21013,190Loss from operations (5,171)(4,727)(14,210)(13,190) Other income (expense): Change in fair value of common stock warrants453-712-Other income (expense), net1105265Total other income (expense), net45410217265Net Loss $(4,717)
(12,925)Net loss per common share – basic and diluted$(0.38)
(1.27)Weighted average common shares outstanding – basic and diluted12,34010,11812,30310,166Celsion CorporationBalance Sheets(in thousands except for per share amounts)ASSETSSeptember 30, 2010 (Unaudited)Dec
|SOURCE Celsion Corporation|
Copyright©2010 PR Newswire.
All rights reserved